Prometheus Biosciences (NASDAQ: RXDX) share today 7th December 2022 gained 176% and Prometheus Biosciences share opened at 105.07 USD from 36.06 USD.
Now let us also know the reason for the rise in the stock of Prometheus Biosciences:
The reason for the rise in the share is that today before the opening of the market, there was news from Prometheus Biosciences that Positive Results for PRA023 in Both the Artemis-UC Phase 2 and Apollo-CD Phase 2A Studies, Enables Pathway to First-in-Class and Best-in-Class Anti-TL1A mAb.
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p
Just because of this news, the stock of Prometheus Biosciences has gained momentum and click here for details
About Prometheus Biosciences:
We’re a different kind of biotech company. At Prometheus Biosciences, our one-of-a-kind precision approach is designed to transform the treatment of immune-mediated diseases—starting with inflammatory bowel disease (IBD).
Click Here For More Latest News